Subscribe to RSS
The quality of life and sleep development in N-ERD patients under therapy with omalizumab
Background The association among chronic sinusitis accompanied by polyp formations (CRSwNP), asthma and non-steroidal antiinflammatory drug is known as NSAID-exacerbated respiratory disease (N-ERD). Recurrent nasal polyps complicate clinical histories of the disease.
Method The aim of the study was to investigate the 16 N-ERD patients (10 w, 6 m, Ø 51 y.) with omalizumab therapy. Acquisition of the following rhinologic and pneumologic parameters (NP- and ACT-score), RSOM-31-score with consequent subscales "sleep" (p = 0,037), "emotions" (p = 0,008) and SF-36-score were examined following the period of 3 months omalizumab therapy.
Results Following 3 months the NP-score was significantly lower (MV 2,9/ MV1,3; p = 0,001) and asthma control significantly elevated (MV 16,5/20,1; p = 0,008). RSOM-31-score (p = 0,001) with consequent subscales "sleep" (p = 0,037), "emotions" (p = 0,008) and SF-36-score (p = 0,001) significantly improved after 3 months omalizumab therapy.
Conclusion The efficacy of omalizumab therapy in N-ERD patients is associated with improved quality of life and sleep.
Article published online:
10 June 2020
© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
© Georg Thieme Verlag KG
Stuttgart · New York